A Neuroscientist’s Guide to Live-Cell Analysis: Techniques & Benefits

Webinar presenters Dana Chase, MD, FACOG,Assistant Professor, Division of Gynecologic Oncology University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, Gynecologic Oncologist, Arizona Oncology, and John Longshore, PhD, FACMG, Director, Molecular Pathology, Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, discuss the link between molecular profiles and disease pathogenesis in ovarian cancer, the clinical significance of PARP inhibition in BRCA1 and/or 2–mutated ovarian cancer, the testing process for BRCA mutations, and the evolving paradigms in tumor and germline BRCA testing in ovarian cancer.

Xdrop® is a microfluid droplet technology that enriches and amplifies long DNA fragments of largely unknown sequence from low sample input. Genomics researchers have coupled it with long and short-read sequencing (Oxford Nanopore, PacBio and Illumina) to gain high-resolution insights into genomic regions that have previously been inaccessible.  Examples of its use in unraveling plant genomes include closing gaps due to poor genome assemblies or low correspondence between reference genome and plant variety, resolving structural rearrangements like transposable elements, and examining gene clusters without performing whole genome sequencing. Xdrop can be applied in relation to QTL mapping and bulk segregant analysis by enabling targeted sequencing of the identified region of interest in several segregating plants with the aim of identifying the polymorphisms either linked to or causing the phenotype of interest. The long-range genomic information (100 kb) and single-molecule resolution achieved with Xdrop target enrichment simplifies working with large and structurally complex genomes with an easy capture design and workflow.

Protein concentration is an obligatory critical quality attribute that is necessary to determine total protein content in biopharmaceutical formulations.

In developing and manufacturing mRNA vaccines and therapeutics, selecting and using the appropriate quality or grade of mRNA raw materials can help you meet critical process, scale, quality, and regulatory needs.